每经AI快讯，有投资者在投资者互动平台提问：贵公司自称已布局东南亚，结果上半年国外营收才500 万。近期日本等多地流感多发，贵公司的海外业务收入可有增加？ （文章来源：每日经济新闻） 英诺特（688253.SH）10月21日在投资者互动平台表示，公司在东南亚市场的已获证产品主要分布在泰 国、马来西亚、缅甸等地区。海外市场开发是一个逐步积累的过程，无法一蹴而就，公司将持续深耕市 场，加快国际市场布局。目前公司在日本尚未开展相关业务，海外营业收入情况请持续关注公司后续披 露的定期报告。 ...

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Core Viewpoint - Innotech's stock performance shows a slight increase of 0.30% on October 15, with a trading volume of 42.12 million yuan, indicating a low financing balance compared to historical levels [1] Financing Summary - On October 15, Innotech had a financing buy amount of 2.59 million yuan and a financing repayment of 5.10 million yuan, resulting in a net financing buy of -2.50 million yuan [1] - As of October 15, the total financing and securities lending balance for Innotech was 17.7 million yuan, which accounts for 8.39% of its circulating market value, indicating a low financing balance below the 20th percentile of the past year [1] - There were no shares sold or repaid in the securities lending segment on October 15, with a total securities lending balance of 0.00 yuan, placing it in the high range above the 80th percentile of the past year [1] Business Performance Summary - As of June 30, Innotech had 7,269 shareholders, a decrease of 2.94% from the previous period, while the average number of circulating shares per person increased by 3.03% to 9,466 shares [2] - For the first half of 2025, Innotech reported an operating income of 276 million yuan, a year-on-year decrease of 34.35%, and a net profit attributable to shareholders of 125 million yuan, down 39.36% year-on-year [2] - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [2] Company Overview - Innotech, established on February 6, 2006, and listed on July 28, 2022, is located in Fengtai District, Beijing, specializing in the research, production, and sales of POCT rapid diagnostic products [1] - The company's main revenue sources include respiratory series products (96.49%), other reagent series (2.99%), and preconception care series (0.51%) [1]

Group 1 - The core viewpoint of the news is that Innotech's stock performance and financing activities indicate a low level of market engagement, with significant declines in revenue and profit reported for the first half of 2025 [1][2]. Group 2 - On October 13, Innotech's stock price fell by 0.75%, with a trading volume of 33.18 million yuan. The financing buy-in amount for the day was 7.07 million yuan, while the net financing buy-in was 3.97 million yuan, leading to a total financing and securities balance of 181 million yuan [1]. - The current financing balance of 181 million yuan accounts for 8.54% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1]. - In terms of securities lending, there were no shares sold or repaid on October 13, with the securities lending balance also at zero, which is above the 80th percentile level over the past year, indicating a high level of inactivity in this area [1]. - As of June 30, the number of Innotech shareholders was 7,269, a decrease of 2.94% from the previous period, while the average circulating shares per person increased by 3.03% to 9,466 shares [2]. - For the first half of 2025, Innotech reported operating revenue of 276 million yuan, a year-on-year decrease of 34.35%, and a net profit attributable to shareholders of 125 million yuan, down 39.36% year-on-year [2]. - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Innotech's stock performance and financial metrics indicate a low financing balance and a significant decrease in revenue and profit for the first half of 2025 [1][2]. Group 2 - On October 10, Innotech's stock rose by 0.39% with a trading volume of 34.74 million yuan. The financing buy amount was 4.84 million yuan, while the financing repayment was 4.92 million yuan, resulting in a net financing buy of -0.08 million yuan. The total financing and securities balance reached 177 million yuan [1]. - As of October 10, the financing balance of Innotech was 177 million yuan, accounting for 8.29% of the circulating market value, which is below the 20th percentile level over the past year, indicating a low financing level [1]. - In terms of securities lending, there were no shares repaid or sold on October 10, with a securities lending balance of 0.00 shares, which is above the 80th percentile level over the past year, indicating a high level [1]. - As of June 30, the number of Innotech shareholders was 7,269, a decrease of 2.94% from the previous period, while the average circulating shares per person increased by 3.03% to 9,466 shares [2]. - For the first half of 2025, Innotech reported operating revenue of 276 million yuan, a year-on-year decrease of 34.35%, and a net profit attributable to the parent company of 125 million yuan, down 39.36% year-on-year [2]. - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [3].

Core Points - Innotec announced the issuance of stock for equity incentive purposes, with a total of 526,120 shares to be listed [1] - The subscription method for the stock is offline, and the total number of shares available for circulation is also 526,120 [1] - The listing date for the stock is set for September 30, 2025 [1]

证券代码：688253 证券简称：英诺特 公告编号：2025-055 北京英诺特生物技术股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第二个 归属期、预留授予部分第一个归属期归属结果暨股份上 市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 526,120股。 本次股票上市流通总数为526,120股。 本次股票上市流通日期为2025 年 9 月 30 日。 北京英诺特生物技术股份有限公司（以下简称"英诺特"或"公司"）于近日 收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》，公 司完成了 2023 年限制性股票激励计划首次授予部分第二个归属期、预留授予部分 第一个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2023 年 8 月 27 日，公司召开第一届董事会第十八次会议，审议通过了 《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议 ...

Core Points - Beijing Innotech Biotechnology Co., Ltd. has completed the registration of changes in business and has obtained a new business license [1][2] - The company held board meetings and a shareholder meeting to approve changes in registered capital, the cancellation of the supervisory board, and amendments to the Articles of Association [1][2] Company Information - The registered capital of the company is 136.458196 million yuan [1] - The company was established on February 6, 2006, and is located in Fengtai District, Beijing [1] - The legal representative of the company is Zhang Xiujie [1] Business Scope - The company engages in various activities including technology services, development, consulting, and transfer, as well as import and export of goods [1] - It is involved in the sale and production of medical devices, including both Class I and Class II medical devices [1]

Core Points - Innotek announced the convening of its 10th meeting of the 2nd Board of Directors on August 27, 2025, and the first extraordinary shareholders' meeting on September 15, 2025, to review proposals regarding changes in registered capital, the cancellation of the supervisory board, and amendments to the articles of association [2] - The company has completed the business registration change procedures and the filing of the articles of association, obtaining a new business license from the Fengtai District Market Supervision Administration in Beijing [2]

证券代码：688253 证券简称：英诺特 公告编号：2025-054 北京英诺特生物技术股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京英诺特生物技术股份有限公司（以下简称"公司"）分别于 2025 年 8 月 27 日、2025 年 9 月 15 日召开第二届董事会第十次会议、2025 年第一次临时股 东大会，审议通过了《关于变更注册资本、取消监事会及修订<公司章程>并办理 工商登记的议案》。具体内容详见公司 2025 年 8 月 29 日、2025 年 9 月 16 日分 别披露于上海证券交易所网站（www.sse.com.cn）的《关于变更注册资本、取消 监事会及修订<公司章程>并办理工商登记的公告》（公告编号：2025-037）、《2025 年第一次临时股东大会决议公告》（公告编号：2025-047）。 近日，公司已完成工商变更登记手续和《公司章程》备案，并取得北京市丰 台区市场监督管理局换发的《营业执照》，基本信息如下： 统一社会信用代码：9111010 ...